Moderna's COVID-19 Vaccine Candidate To Enter Phase 3 Trial

Moderna's preliminary vaccine trials showed promising results, with all 45 participants developing antibodies against COVID-19. The trial involved administering the vaccine twice at varying dosages, with higher dosages yielding stronger antibodies. Side effects were mild, including pain at the injection site, headache, chills, and muscle pain. Unlike traditional vaccines, Moderna's uses mRNA to trigger an immune response. The vaccine may offer protection for up to two years. Phase three of the trial is set to begin on July 27th with 30,000 participants.

What were the results of the preliminary vaccine trials conducted by Moderna?

How many people participated in the Moderna vaccine trial?

What side effects were reported by participants in the Moderna vaccine trial?

What type of genetic material does Moderna's vaccine carry?

When is Moderna set to begin phase three of its vaccine trial?